Reduction of unnecessary antibiotic administration, adverse events, hospitalizations, and cost:

By quickly identifying the specific pathogens causing the UTI and their antibiotic resistance profiles, the panel helps healthcare providers make informed decisions about targeted antibiotic therapy. This reduces the overuse of broad-spectrum antibiotics, minimizes the risk of adverse events, prevents unnecessary hospitalizations, and lowers healthcare costs.

Testing for resistance genes targeting specific antibiotic classes:

The InGenDX UTI Panel can detect resistance genes associated with different classes of antibiotics. This information enables healthcare providers to select the most appropriate antibiotics for effective treatment, considering the resistance patterns of the identified pathogens.

Prevention of dangerous complications:

UTIs can lead to severe complications, such as kidney infections or bloodstream infections. The rapid and accurate diagnosis provided by the panel helps initiate prompt treatment, reducing the risk of complications and improving patient outcomes.

High specificity:

The panel offers high specificity, meaning it can accurately identify the presence of specific pathogens and their resistance profiles in UTIs. This specificity helps ensure targeted and effective treatment.

Detection of multiple pathogens in a single specimen:

The InGenDX UTI Panel has the capability to detect multiple pathogens simultaneously in a single specimen. This comprehensive analysis provides a more thorough understanding of the infection, allowing for tailored treatment plans.

Quick and accurate results:

The panel provides results within 12 hours once the specimen is received by the laboratory. This significantly reduces the turnaround time compared to traditional culture and sensitivity testing, which typically takes 3-5 days. The faster diagnosis allows for timely initiation of appropriate treatment, leading to better patient care and outcomes.